1. Rituximab hypersensitivity: evaluation, desensitization, and potential mechanisms;Wong;J Allergy Clin Immunol,2017
2. Pan American League of Associations for Rheumatology guidelines for the treatment of ANCA-associated vasculitis;Magri;Lancet Rheumatol,2023
3. Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial;Verhoef;Lancet Rheumatol,2019
4. Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications;Kotchetkov;Int J Cancer,2020
5. Crespo A , Forbes L , Gallo-Hershberg D , Management of cancer medication related infusion reactions. Cancer Care Ontario; 2019. [Internet. Accessed April 26, 2024.] Available from: https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/ManagementCancerMedicationRelatedInfusionReactions.pdf